Earn 0.5 CE/CME credits: physicians, nurses, pharmacists! Expert faculty @mkosiborodmd #medtwitter @academiccme #cardiotwitter
— cardio-met (@cardiomet_CE) February 25, 2021
2) Accredited for 0.5 credits by @academiccme: physicians, nurses, pharmacists! Expert faculty @mkosiborodmd Supported by Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. Follow this thread for credit. #cardiotwitter #medtwitter @MedTweetorials
— cardio-met (@cardiomet_CE) February 26, 2021
4) Come back and see the answer tomorrow! @iMedEducation @HFSA @CuriousClinPod #medicine #NurseTwitter #MedEd #Pharmacist #residents #Fellows #Cardiology #cardiovasculardisease #diabetes #heartfailure #renal #hospitalist @RpratleyMD #ruralhealth @beaverspharmd
— cardio-met (@cardiomet_CE) February 26, 2021
— cardio-met (@cardiomet_CE) February 27, 2021
8) Another clear benefit that emerged was on reducing the risk of kidney disease progression pic.twitter.com/TE54YJkuiY
— cardio-met (@cardiomet_CE) February 27, 2021
10) Importantly, HF benefits were seen regardless of baseline HbA1c
— cardio-met (@cardiomet_CE) February 27, 2021
12) So answer this: DAPA-HF Trial, the first large trial of SGLT2i in HFrEF, demonstrated that dapagliflozin, as compared with placebo . . .
— cardio-met (@cardiomet_CE) February 27, 2021
14) Welcome back to our accredited Twitter Journal Club! The correct answer is C. In the DAPA-HF Trial, dapagliflozin significantly reduced the primary endpoint of CV death or worsening HF pic.twitter.com/pLatmhmach
— cardio-met (@cardiomet_CE) February 28, 2021
16) Furthermore, dapagliflozin significantly reduced both components of the primary composite endpoint – worsening HF AND CV death. pic.twitter.com/7laE2FsfI9
— cardio-met (@cardiomet_CE) February 28, 2021
18) And so the stage is set now to turn to our journal club article – a more detailed look at the effects of dapagliflozin in the DAPA-HF Trial in patients with and without Type 2 Diabeteshttps://t.co/CXqfV4FtsV
— cardio-met (@cardiomet_CE) February 28, 2021
20) The answer is False. The effects of dapagliflozin on the primary endpoint were consistent regardless of Type 2 diabetes status pic.twitter.com/NWLpONQbjK
— cardio-met (@cardiomet_CE) February 28, 2021
22)
— cardio-met (@cardiomet_CE) February 28, 2021
A) There was a linear relationship: greater benefit observed with higher HbA1c
B)There was an inverse relationship: smaller benefit observed with higher HbA1c
C)The relationship was a flat line: same benefit regardless of baseline HbA1c
Don’t look down without answering!
24) You’re on a roll! One last question: What are some of the advantages of using SGLT2i in patients with HFrEF and no prior history of T2D?
— cardio-met (@cardiomet_CE) February 28, 2021
Return tomorrow for the answer to this final poll and for a link to earn your CE credit: physicians, nurses, pharmacists! #MedTwitter #MedEd #heartfailure @PokrajacAna @JavedButler1 @robmentz @PepaSolerR @biljana_parapid @CMichaelGibson @DrJessePines
— cardio-met (@cardiomet_CE) February 28, 2021
25) You made it! Free CE/CME! The correct answer is D – All of the above. Now go to https://t.co/MWboTIFeDk and claim your credit! I am @mkosiborodmd. Follow @cardiomet_CE for more tweetorials! #medtwittter #cardiotwitter
— cardio-met (@cardiomet_CE) March 1, 2021